282 related articles for article (PubMed ID: 18767046)
21. Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study.
Jun JK; Choi KS; Jung KW; Lee HY; Gapstur SM; Park EC; Yoo KY
Int J Cancer; 2009 Jan; 124(1):188-93. PubMed ID: 18785204
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
23. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
[TBL] [Abstract][Full Text] [Related]
24. [Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996].
Bos AB; van Ballegooijen M; van den Akker-van Marle ME; Habbema JD
Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1586-90. PubMed ID: 12224483
[TBL] [Abstract][Full Text] [Related]
25. The evaluation of cervical cancer screening by combining speculoscopy with Papanicolaou smear examination in Taiwan.
Chang JI; Ou CH; Wu KM; Chen CC; Cheng KC
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Sep; 65(9):430-4. PubMed ID: 12433029
[TBL] [Abstract][Full Text] [Related]
26. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001.
van der Aa MA; Schutter EM; Looijen-Salamon M; Martens JE; Siesling S
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):204-9. PubMed ID: 18093720
[TBL] [Abstract][Full Text] [Related]
27. A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003.
Morrell S; Taylor R; Wain G
J Med Screen; 2005; 12(4):190-6. PubMed ID: 16417696
[TBL] [Abstract][Full Text] [Related]
28. Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
Yu SC; Huang HH; Li CC; Tang JL; Lee YH; Mao TL; Kuo KT; Lin CT; Liu JH; Ko BS; Yao M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1367-1373. PubMed ID: 28450182
[TBL] [Abstract][Full Text] [Related]
29. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan.
Sung HY; Kearney KA; Miller M; Kinney W; Sawaya GF; Hiatt RA
Cancer; 2000 May; 88(10):2283-9. PubMed ID: 10820350
[TBL] [Abstract][Full Text] [Related]
30. Papanicolaou smear screening and cervical cancer. What can you expect?
Stenkvist B; Bergström R; Eklund G; Fox CH
JAMA; 1984 Sep; 252(11):1423-6. PubMed ID: 6471269
[TBL] [Abstract][Full Text] [Related]
31. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme.
Confortini M; Giorgi Rossi P; Barbarino P; Passarelli AM; Orzella L; Tufi MC
J Med Screen; 2010; 17(2):79-86. PubMed ID: 20660436
[TBL] [Abstract][Full Text] [Related]
32. [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening].
Berkers LM; van Ballegooijen M; van Kemenade FJ; Rebolj M; Essink-Bot ML; Helmerhorst TJ; Habbema JD
Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1288-94. PubMed ID: 17624160
[TBL] [Abstract][Full Text] [Related]
33. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study.
Rebolj M; van Ballegooijen M; Lynge E; Looman C; Essink-Bot ML; Boer R; Habbema D
BMJ; 2009 Apr; 338():b1354. PubMed ID: 19395420
[TBL] [Abstract][Full Text] [Related]
34. Pap smear intervals safe.
AIDS Patient Care STDS; 2000 Dec; 14(12):675. PubMed ID: 11119436
[No Abstract] [Full Text] [Related]
35. Adequacy of cellular material in split-sampling of cervical scrapings for routine cancer screening: an analysis of 702 smears.
Othman N; Othman NH
Malays J Pathol; 2012 Dec; 34(2):115-21. PubMed ID: 23424773
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of Pap smear screening of high risk aboriginal women. Use of a computerised process tool within the Broome Aboriginal Medical Service.
Couzos S; Wronski I; Murray R; Cox H
Aust Fam Physician; 1998 Apr; 27(4):269-74. PubMed ID: 9581335
[TBL] [Abstract][Full Text] [Related]
37. The frequency of having pap-smear tests among women between 15-64 years old and the evaluation of the level of their knowledge.
Sevil S; Kevser O; Aleattin U; Ozlem D
J Pak Med Assoc; 2013 Jul; 63(7):873-7. PubMed ID: 23901712
[TBL] [Abstract][Full Text] [Related]
38. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
[TBL] [Abstract][Full Text] [Related]
39. Prospective and randomised public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the first year.
Nieminen P; Hakama M; Viikki M; Tarkkanen J; Anttila A
Int J Cancer; 2003 Jan; 103(3):422-6. PubMed ID: 12471627
[TBL] [Abstract][Full Text] [Related]
40. Risk factors of cervical cancer after a negative cytological diagnosis in Polish cervical cancer screening programme.
Macios A; Didkowska J; Wojciechowska U; Komerska K; Glińska P; Kamiński MF; Nowakowski A
Cancer Med; 2021 May; 10(10):3449-3460. PubMed ID: 33934537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
